Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sinocelltech Group Limited (688520.SS)
CNY38.20
+1.94 (+5.35%)
CN SHH Healthcare Biotechnology
Address
No. 31 Kechuang 7th Street 100176
Beijing, CN
Beijing, CN
CEO
Liangzhi Xie
Website
sinocelltech.com
IPO
2020-06-22
ISIN CNE100003ZL3
Description
Sinocelltech Group Limited is a Beijing-based biotechnology enterprise. The company's primary focus lies in pioneering and refining the technologies required for both the creation and large-scale production of vital biological agents, specifically recombinant proteins, monoclonal antibodies, and vaccines, throughout China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY38.20
+1.94 (+5.35%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.57
Float Shares
48.50M
Free Float %
10.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.48% | +2.03% | +1.93% | +6.75% | -14.85% | -1.39% | +18.54% | -30.39% | -7.85% | -41.55% | -41.55% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
38.20
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.10
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-37.9% Q1'26: -38.3% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-637.5% Q1'26: -415.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-37.1% Q1'26: -55.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-35.6% Q1'26: -40.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-29.8% Q1'26: -21.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-8.1% ★ Q1'26: -12.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-6.01× Q1'26: -7.48× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.02B
est: 1.02B (+0.0%)
|
1.89B
est: 2.38B (-20.8%)
|
2.51B
est: 2.52B (-0.2%)
|
1.56B
est: 2.19B (-28.9%)
|
2.54B
2.54B – 2.54B
+15.9% YoY
|
3.02B
3.02B – 3.02B
+18.8% YoY
|
4.75B
4.75B – 4.75B
+57.2% YoY
|
| EBITDA |
-378.76M
est: -386.19M (+1.9%)
|
-190.86M
est: -769.29M (+75.2%)
|
339.51M
est: -812.24M (+141.8%)
|
-432.62M
est: -708.00M (+38.9%)
|
-820.62M
-820.62M – -820.62M
-15.9% YoY
|
-974.87M
-974.87M – -974.87M
-18.8% YoY
|
-1.53B
-1.53B – -1.53B
-57.2% YoY
|
| EBIT |
-435.58M
est: -417.72M (-4.3%)
|
-285.31M
est: -880.06M (+67.6%)
|
217.51M
est: -929.20M (+123.4%)
|
-554.62M
est: -809.94M (+31.5%)
|
-938.78M
-938.78M – -938.78M
-15.9% YoY
|
-1.12B
-1.12B – -1.12B
-18.8% YoY
|
-1.75B
-1.75B – -1.75B
-57.2% YoY
|
| Net Income |
-519.00M
est: -545.76M (+4.9%)
|
-396.02M
est: -127.07M (-211.7%)
|
111.95M
est: 107.23M (+4.4%)
|
-553.29M
est: -30.02M (-1,742.9%)
|
60.05M
60.05M – 60.05M
+300.0% YoY
|
223.03M
223.03M – 223.03M
+271.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
395.32M
est: 88.46B (-99.6%)
|
584.10M
est: 1.57B (-62.7%)
|
881.63M
est: 1.65B (-46.7%)
|
625.15M
est: 1.44B (-56.6%)
|
1.67B
1.67B – 1.67B
+15.9% YoY
|
1.99B
1.99B – 1.99B
+18.8% YoY
|
3.12B
3.12B – 3.12B
+57.2% YoY
|
| EPS |
-1.19
est: -1.17 (-1.7%)
|
-0.89
est: -0.30 (-200.4%)
|
0.24
est: 0.25 (-4.0%)
|
-1.29
est: -0.07 (-1,742.9%)
|
0.14
0.14 – 0.14
+300.0% YoY
|
0.52
0.52 – 0.52
+271.4% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.37B
OE per share TTM
-4.30
Owner's Yield
-7.39%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
100.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.05% | 17.1K | 0.65% |
| 2 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 6.7K | 0.15% |
| 3 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 483.8K | 0.06% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 38.3K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 17.0K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.89M | 0.06% |
| 7 | Vanguard ESG International Stock ETF VSGX | 0.00% | 25.9K | 0.10% |
| 8 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.91M | 0.05% |
| 9 | Goldman Sachs MarketBeta Total International Equity ETF GXUS | 0.00% | 1.7K | 0.18% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 127.3K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-239.8K
Shares Outstanding
470.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chun Xia Luo | Person in charge of Pilot & Production Workshop | — | female |
| Chun Yun Sun | Executive Director of Preclinical R&D Center | — | female |
| Fanbin Pan | Head of Engineering Equipment Department | — | male |
| Jie Ma | Accounting Supervisor & Financial Director | — | female |
| Li Ming Tang | Deputy GM, Secretary of the Board & Director | — | male |
| Liangzhi Xie | Chairman of the Board & GM | — | — |
| Yan Jing Zhang | Executive Director of Preclinical R&D Center | — | female |
| Yang Wang | Deputy GM & Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688520.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
